Form 4: Ionis Director Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Ionis Pharmaceuticals Director Allene M. Diaz sold 1,427 shares of common stock for approximately $42.53 per share under a pre-arranged trading plan.
Summary
- Allene M. Diaz, a Director at IONIS PHARMACEUTICALS INC (IONS), reported the sale of 1,427 shares of common stock.
- The transaction occurred on August 22, 2025, at a weighted average price of $42.5278 per share.
- The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Ms. Diaz on May 3, 2023.
- Following this transaction, Ms. Diaz directly beneficially owns 18,368 shares of common stock.
- The sale price for the shares ranged from $42.30 to $42.75 per share.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale under a pre-arranged 10b5-1 plan, which is generally considered neutral as it does not reflect new discretionary trading decisions or significant changes in company fundamentals.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction under a pre-arranged trading plan and does not provide specific insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholders, as it is a pre-scheduled event rather than a discretionary sale based on new information.
Key Dates
| Date | Description |
|---|---|
| May 3, 2023 | Rule 10b5-1 Trading Plan adopted by Allene M. Diaz. |
| August 22, 2025 | Date of common stock transaction (sale). |
| August 26, 2025 | Date the Form 4 was signed by attorney-in-fact for Allene M. Diaz. |
Recommendation
holdThe reported transaction is a routine insider sale executed under a Rule 10b5-1 trading plan, which was adopted well in advance. Such pre-scheduled sales by a director typically do not indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter the investment thesis for IONIS PHARMACEUTICALS INC.
Keywords
Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Sale, Allene M. Diaz, 10b5-1 Plan, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.